News

The Emergency Center Arizona (TEA) Rebrands to Canyon State Emergency Partners (CSEP) to Reflect Local Dedication and Physician-Led Model

PHOENIX, ARIZONA / ACCESS Newswire / December 11, 2025 / The Emergency Center Arizona (TEA), one of the largest physician-led…

2 weeks ago

AIML Announces Engagement of Guerilla Capital for Communications and Investor Outreach Efforts

TORONTO, ON / ACCESS Newswire / December 11, 2025 / AI/ML Innovations Inc. (CSE:AIML) ("AIML" or the "Company") is pleased…

2 weeks ago

Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv

The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated…

2 weeks ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent,…

2 weeks ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership,…

2 weeks ago

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

isupartob sodium product picture Product picture of isupatob sodium (formally known as M6229), which is a treatment in clinical development…

2 weeks ago

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY,…

2 weeks ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)…

2 weeks ago

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off…

2 weeks ago

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH…

2 weeks ago